Ambrisentan not effective in idiopathic pulmonary fibrosis

Ambrisentan not effective in idiopathic pulmonary fibrosis
The endothelin A receptor-selective antagonist ambrisentan is not effective for reducing the rate of idiopathic pulmonary fibrosis progression, according to a study published in the May 7 issue of the Annals of Internal Medicine.

(HealthDay)—The endothelin A receptor-selective antagonist ambrisentan is not effective for reducing the rate of idiopathic pulmonary fibrosis (IPF) progression, according to a study published in the May 7 issue of the Annals of Internal Medicine.

To examine whether ambrisentan reduces the rate of IPF progression, Ganesh Raghu, M.D., from the University of Washington in Seattle, and colleagues randomized patients (aged 40 to 80 years) with IPF, with minimal or no honeycombing on high-resolution computed tomography scans, to receive ambrisentan (10 mg/day) or placebo.

Noting that interim analysis indicated a low likelihood of showing efficacy for the end point by the scheduled end of the study, the researchers terminated the study after enrollment of 492 patients (75 percent of intended enrollment; mean duration of exposure to study medication, 34.7 weeks). There was a significantly increased likelihood of meeting the prespecified criteria for disease progression among the ambrisentan-treated versus placebo-treated patients (27.4 percent versus 17.2 percent; hazard ratio, 1.74). The decline in lung function was seen in 16.7 percent of ambrisentan-treated patients and in 11.7 percent of placebo-treated patients (P = 0.11). Respiratory hospitalizations were significantly higher in the ambrisentan group than the (13.4 versus 5.5 percent, respectively). There was a nonsignificant difference in the number of deaths between the two groups (7.9 percent of ambrisentan-treated and 3.7 percent of placebo-treated patients; P = 0.10).

"Ambrisentan was not effective in treating IPF and may be associated with an increased risk for disease progression and respiratory hospitalizations," the authors write.

Several authors disclosed to pharmaceutical companies, including Gilead Sciences, which funded the study.

More information: Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Vitreolytic ocriplasmin resolves vitreomacular traction

Aug 16, 2012

(HealthDay) -- Intravitreal injection of the vitreolytic agent ocriplasmin resolves vitreomacular traction and closes macular holes significantly better than placebo, but with a higher incidence of adverse ...

Recommended for you

Routines most vital in avoiding Ebola infection: WHO

1 minute ago

Meticulously following stringent routines when putting on and removing protective equipment is more important than the kind of gear health care workers use to ward off Ebola infection, the World Health Organization said Friday.

A look at latest Ebola developments

1 hour ago

No African countries are on the United Nations list of contributors to fight Ebola. With few exceptions, African governments and institutions are offering only marginal support as the continent faces its ...

Liberia opens one of largest Ebola treatment centers

1 hour ago

Liberia's president opened one of the country's largest Ebola treatment centers in Monrovia on Friday, remembering the days when "the dying, the sick, the dead who could not picked up on time" as officials ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.